login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
PROTALIX BIOTHERAPEUTICS INC (PLX) Stock News
USA
- NYSEARCA:PLX -
US74365A3095
-
Common Stock
2.13
USD
0 (0%)
Last: 11/11/2025, 8:04:00 PM
2.1494
USD
+0.02 (+0.91%)
After Hours:
11/11/2025, 8:04:00 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
PLX Latest News, Press Relases and Analysis
All
Press Releases
7 days ago - By: Schall Law
PLX Investors Have Opportunity to Join Protalix BioTherapeutics, Inc. Fraud Investigation with the Schall Law Firm
11 days ago - By: The Schall Law Firm
PLX Investors Have Opportunity to Join Protalix BioTherapeutics, Inc. Fraud Investigation with the Schall Law Firm
15 days ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Protalix BioTherapeutics, Inc. - PLX
26 days ago - By: Stocktwits
- Mentions:
IWMW
URTY
Protalix BioTherapeutics Stock Tumbled 28% Today: Why The Latest CHMP Opinion Is Sparking Concerns Among Investors?
3 months ago - By: The Motley Fool
Protalix Revenue Jumps 16 Percent in Q2
3 months ago - By: Benzinga
Preview: Protalix BioTherapeutics's Earnings
6 months ago - By: Benzinga
Uncovering Potential: Protalix BioTherapeutics's Earnings Preview
20 days ago - By: Pomerantz LLP
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Protalix BioTherapeutics, Inc. - PLX
2 months ago - By: ACCESS Newswire
- Mentions:
UXIN
JG
PRSO
SPCB
...
Presenting at the Investor Summit Q3 2025 on September 16; Watch the Live Stream for Free
2 months ago - By: ACCESS Newswire
Protalix BioTherapeutics to Present at Investor Summit Virtual
7 months ago - By: Stocktwits
- Mentions:
RGLS
NVS
ZVRA
ESPR
...
Regulus Downgraded By Analysts After $1.7B Novartis Buyout Offer — Street Sees Limited Upside Ahead
8 months ago - By: ACCESS Newswire
- Mentions:
NXGL
DTST
ACCS
CJMB
...
iAccess Alpha's Virtual Best Ideas Spring Investment Conference March 25-26, 2025
a year ago - By: Kaskela Law LLC
Kaskela Law LLC Announces Shareholder Investigation of Protalix BioTherapeutics, Inc. (NYSE: PLX) and Encourages Investors to Contact the Firm
a year ago - By: Virtual Investor Conferences
- Mentions:
VNRX
APRE
CHRO
ACST
...
Life Sciences Virtual Investor Forum Agenda Announced for September 19th
a year ago - By: InvestorPlace
PLX Stock Earnings: Protalix BioTherapeutics Misses EPS, Beats Revenue for Q2 2024
2 years ago - By: InvestorPlace
PLX Stock Earnings: Protalix BioTherapeutics Misses EPS, Misses Revenue for Q1 2024
Please enable JavaScript to continue using this application.